Authors: Yoshiyuki Yamagishi Hajime Higuchi Motoko Izumiya Gen Sakai Hideko Iizuka Shoko Nakamura Masayuki Adachi Sigenari Hozawa Hiromasa Takaishi Toshifumi Hibi
Publish Date: 2010/06/15
Volume: 45, Issue: 11, Pages: 1146-1154
Abstract
Gemcitabine GEM is the key drug for the chemotherapy of unresectable pancreatic cancer However the efficacy and safety of GEM has not been established in elderly patients We retrospectively examined the prognosis of elderly pancreatic cancer patients treated with GEMSixtysix patients with unresectable pancreatic cancer pathologically identified and no prior chemotherapy were divided into three groups Group A patients aged 70 years or more who received standard GEM 1000 mg/m2 on days 1 8 and 15 and rest on day 21 Group B patients less than 70 years old who received standard GEM therapy and Group C patients under best supportive careMedian survival times MSTs days were 311 in group A p 005 vs group C 292 in group B p 005 vs group C and 127 in group C Among the patients who received GEM 23 patients in group A and 16 patients in group B obtained partial responses The response rates and MSTs were similar in groups A and B as well as in more aged ≥75 years patients Bone marrow suppression was more frequently seen in elderly patients Cox’s hazard model in patients aged 70 years or more revealed that GEM therapy reduced the hazard ratio for death hazard ratio 0683 p = 0041
Keywords: